↓ Skip to main content

Low-dose aspirin and survival from lung cancer: a population-based cohort study

Overview of attention for article published in BMC Cancer, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
2 news outlets
twitter
6 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Low-dose aspirin and survival from lung cancer: a population-based cohort study
Published in
BMC Cancer, November 2015
DOI 10.1186/s12885-015-1910-9
Pubmed ID
Authors

Úna C. Mc Menamin, Chris R. Cardwell, Carmel M. Hughes, Liam M. Murray

Abstract

Preclinical evidence suggests that aspirin may inhibit lung cancer progression. In a large cohort of lung cancer patients, we investigated whether low-dose aspirin use was associated with a reduction in the risk of lung cancer-specific mortality. We identified lung cancer patients from English cancer registries diagnosed between 1998 to 2009 from the National Cancer Data Repository. Medication usage was obtained from linkages to the UK Clinical Practice Research Datalink and lung cancer-specific deaths were identified from Office of National Statistics mortality data. Hazard ratios (HR) and 95 % confidence intervals (CI) for the association between low-dose aspirin use (before and after diagnosis) and risk of lung cancer-specific mortality were calculated using Cox regression models. A total of 14,735 lung cancer patients were identified during the study period. In analysis of 3,635 lung cancer patients, there was no suggestion of an association between low-dose aspirin use after diagnosis and cancer-specific mortality (adjusted HR = 0.96, 95 % CI: 0.85, 1.09). Similarly, no association was evident for low-dose aspirin use before diagnosis and cancer-specific mortality (adjusted HR = 1.00, 95 % CI: 0.95, 1.05). Associations were comparable by duration of use and for all-cause mortality. Overall, we found little evidence of a protective association between low-dose aspirin use and cancer-specific mortality in a large population-based lung cancer cohort.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 35%
Student > Ph. D. Student 6 19%
Student > Master 3 10%
Student > Postgraduate 2 6%
Student > Bachelor 1 3%
Other 4 13%
Unknown 4 13%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 8 26%
Medicine and Dentistry 6 19%
Agricultural and Biological Sciences 3 10%
Biochemistry, Genetics and Molecular Biology 3 10%
Economics, Econometrics and Finance 2 6%
Other 2 6%
Unknown 7 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2021.
All research outputs
#1,391,637
of 19,862,278 outputs
Outputs from BMC Cancer
#205
of 7,114 outputs
Outputs of similar age
#30,730
of 385,322 outputs
Outputs of similar age from BMC Cancer
#20
of 770 outputs
Altmetric has tracked 19,862,278 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,114 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 385,322 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 770 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.